US Stock MarketDetailed Quotes

AVDL Avadel Pharmaceuticals

Watchlist
  • 18.820
  • +0.520+2.84%
Close May 3 16:00 ET
  • 18.840
  • +0.020+0.11%
Post 18:27 ET
1.81BMarket Cap-9410P/E (TTM)

About Avadel Pharmaceuticals Company

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

Company Profile

SymbolAVDL
Company NameAvadel Pharmaceuticals
Listing DateJun 6, 1996
Issue Price10.39
Founded2015
CEOMr. Gregory J. Divis
MarketNASDAQ
Employees154
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
Address10 Earlsfort Terrace
CityDublin
ProvinceDublin
CountryIreland
Zip Code02
Phone353-1-901-5201
Websitehttp://www.avadel.com

Company Executives

  • Name
  • Position
  • Salary
  • Gregory J. Divis
  • Director and Chief Executive Officer
  • 753.69K
  • Thomas S. Mchugh
  • Chief Financial Officer and Principal Accounting Officer
  • 526.00K
  • Richard Kim
  • Chief Commercial Officer
  • 548.44K
  • Geoffrey M. Glass
  • Non-Executive Chairman of the Board
  • 257.12K
  • Peter J. Thornton
  • Independent Director
  • 237.53K
  • Dr. Mark A. Mccamish, M.D.,PhD
  • Independent Director
  • 227.53K
  • Linda S. Palczuk
  • Independent Director
  • 230.03K
  • Dr. Eric J. Ende, M.B.A.,M.D.
  • Independent Director
  • 230.03K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg